Medication Therapy Management (MTM)
Pharmacists are the primary providers of Medication Therapy Management (MTM). In order to recognize and deal with medication-related issues, the MTM pharmacist examines all prescription drugs written by all physicians who are treating the patient. Also, they examine any over-the-counter and herbal items the patient may be taking.
An untreated or improperly managed disease may need the administration of medicine(s). This can lead to issues such as incorrect drug usage, medication duplication, and wasteful medication use. To create and accomplish the best possible drug treatment goals, MTM entails working in coordination with the patient, doctor, and other healthcare professionals.
Components of Medication Therapy Management
Medication therapy management involves numerous essential components:
Comprehensive Medication Review (CMR)
A pharmacist gathers details on the patient’s prescription treatment and recognizes medication-related issues. Also, he developed a strategy to address them during the CMR. Along with teaching patients the significance of medication adherence, the chemist may also provide instructions on how to take prescriptions.
Personal Medication List (PML)
A current list of the patient’s prescriptions refers to the PML. It might consist of the indications and the patient’s drug regimen. When the patient’s prescriptions change, they should update their list.
To-Do List (TDL)
The TDL is a report that outlines the steps the patient can execute to take care of their drugs on their own. The TDL’s suggestions are either within the chemist’s area of practice or have been approved by the appropriate medical team members.
Intervention and/or Referral
By contacting prescribers or directing patients to another medical specialist, the pharmacist steps in to act on behalf of the patient. Certain patients may require elaborate interventions as part of their extremely specific treatment plans. For instance, chemotherapies or treatments for autoimmune diseases.
Documentation and Follow-up
The MTM documentation follows a standard structure and comprises a visit report. It is a crucial part of MTM as it enables the chemist to guarantee care continuity across various providers and locations. Also, it is necessary for billing and reimbursement purposes.
MTM as an Element of PDPs and MA-PDs’ Medicare Part D Drug Benefit
In order to maximize therapeutic results, Medicare Advantage Plans (MAPDs) and Part D Prescription Drug Plans (PDPs) must establish MTM programs that offer relevant services to chosen beneficiaries. Targeted beneficiaries under Part D are often individuals who:
- Having several long-term illnesses
- Using many Part D-covered drugs
- Possibility of yearly medicine expenditures exceeding a particular level.
The number and variety of chronic illnesses, as well as the number of Part D drugs, that entitle its users to MTM services, are subject to considerable discretion on the part of Part D plans. Because of this, there are significant differences within Part D plans about who is eligible for MTM treatments as well as the kind and scope of those services.
Some users who may benefit from these services are now unable to receive them under their plans. Despite this variance being understandable at the beginning of the Part D program.
MTM Services Offer Benefits
MTM services add value and support the wise, safe, and efficient use of pharmaceuticals by:
- Enhancing the standard of patient treatment and results (such as better adherence, disease/symptom recovery, and life preservation);
- Lowering the cost of health care (e.g., by cutting back on hospital stays, urgent/emergency care visits, and doctor visits);
- Lowering adverse drug-related occurrences (e.g., increased patient safety).